Loading...
•
Sep 30, 2022
Guardant Health Q3 2022 Earnings Report
Reported a revenue increase of 24% year-over-year, driven by growth in clinical and biopharma testing volumes.
Key Takeaways
Guardant Health reported revenue of $117.4 million for the third quarter of 2022, a 24% increase compared to the same period in 2021. The growth was primarily driven by a 42% increase in clinical testing volume and a 40% increase in biopharma sample volume. The company also made progress on the ECLIPSE study and the Shield LDT screening test.
Revenue of $117.4 million for the third quarter of 2022, an increase of 24% over the corresponding period of 2021
Reported 32,400 tests to clinical customers and 6,750 tests to biopharmaceutical customers in the third quarter of 2022, representing an increase of 42% and 40%, respectively, over the third quarter of 2021
Expanded Guardant Reveal™ , the only tissue-free liquid biopsy test for detection of residual and recurrent disease, to include early-stage breast and lung cancers in addition to colorectal cancer
Received FDA approval for Guardant360® CDx liquid biopsy test as a companion diagnostic for ENHERTU® for treatment of non-small cell lung cancer patients with activating HER2 mutations
Revenue by Segment
Forward Guidance
Guardant Health now expects full year 2022 revenue to be in the range of $440 million to $450 million, representing growth of 18% to 20% compared to full year 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...